×
About 24,665 results

ALLMedicine™ Lymphomas Center

Research & Reviews  7,552 results

Therapy Resistance Mechanisms in Hematological Malignancies.
https://doi.org/10.1002/ijc.34243
International Journal of Cancer; Hofmann WK, Trumpp A et. al.

Aug 14th, 2022 - Hematologic malignancies are model diseases for understanding neoplastic transformation and serve as prototypes for developing effective therapies. Indeed, the concept of systemic cancer therapy originated in hematologic malignancies and has guide...

Relapsed Angioimmunoblastic T Cell Lymphoma with Fulminant Leukemic Involvement.
https://doi.org/10.12659/AJCR.936448
The American Journal of Case Reports; Altahan R, AlMugairi A et. al.

Aug 13th, 2022 - BACKGROUND Angioimmunoblastic T cell lymphoma (AITL) is an aggressive and rare entity that comprises about 1-2% of all non-Hodgkin lymphomas. This entity carries many challenges that start at the diagnosis, as most patients present with non-specif...

Generation of a CRISPR activation mouse that enables modelling of aggressive lymphoma a...
https://doi.org/10.1038/s41467-022-32485-9
Nature Communications; Deng Y, Diepstraten ST et. al.

Aug 13th, 2022 - CRISPR technologies have advanced cancer modelling in mice, but CRISPR activation (CRISPRa) methods have not been exploited in this context. We establish a CRISPRa mouse (dCas9a-SAMKI) for inducing gene expression in vivo and in vitro. Using dCas9...

Doxorubicin, CC-(486) (5-azacitidine), Romidepsin, and Duvelisib (hARD) for T-cell Lymphoma
https://clinicaltrials.gov/ct2/show/NCT04639843

Aug 12th, 2022 - Background: T-cell lymphomas (TCLs) are a heterogeneous group of lymphoid malignancies defined by clonal proliferation of post-thymic T lymphocytes. Patients with newly diagnosed TCLs are most commonly treated with a CHOP (cyclophosphamide, doxoru...

Treatment by a Bispecific CD3xCD20 Antibody for Relapse/Refractory Lymphomas After CAR T-cells Therapy
https://clinicaltrials.gov/ct2/show/NCT04703686

Aug 12th, 2022 - This study is a multicenter phase II trial including 2 cohorts of patients in Refractory/Relapse disease at least 1 month after CAR T-cells therapy: cohort 1: DLBCL patients cohort 2: PMBL, mantle cell lymphoma, transformed indolent NHL (t-iNHL) o...

see more →

Guidelines  24 results

T-Cell Lymphomas, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology.
https://doi.org/10.6004/jnccn.2022.0015
Journal of the National Comprehensive Cancer Network : JN... Horwitz SM, Ansell S et. al.

Mar 12th, 2022 - Peripheral T-cell lymphomas (PTCLs) are a heterogeneous group of lymphoproliferative disorders arising from mature T cells, accounting for about 10% of non-Hodgkin lymphomas. PTCL-not otherwise specified is the most common subtype, followed by ang...

American Registry of Pathology Expert Opinions: Recommendations for the diagnostic work...
https://doi.org/10.1016/j.anndiagpath.2020.151623
Annals of Diagnostic Pathology; Vega F, Amador C et. al.

Sep 19th, 2020 - The diagnosis of T-cell lymphomas is highly challenging and requires an integrated approach in which clinical, morphologic, immunophenotypic and molecular data are incorporated into the diagnosis. Under the auspices of the American Registry of Pat...

Pediatric Aggressive Mature B-Cell Lymphomas, Version 2.2020, NCCN Clinical Practice Gu...
https://doi.org/10.6004/jnccn.2020.0036
Journal of the National Comprehensive Cancer Network : JN... Davies K, Barth M et. al.

Aug 7th, 2020 - Pediatric aggressive mature B-cell lymphomas are the most common types of non-Hodgkin lymphoma in children, and they include Burkitt lymphoma (BL) and diffuse large B-cell lymphoma (DLBCL). These diseases are highly aggressive but curable, the tre...

Marginal zone lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and...
https://doi.org/10.1016/j.annonc.2019.10.010
Annals of Oncology : Official Journal of the European Soc... Zucca E, Arcaini L et. al.

Jan 9th, 2020 - Marginal zone lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.|2020|Zucca E,Arcaini L,Buske C,Johnson PW,Ponzoni M,|diagnosis,epidemiology,therapy,

Primary extranodal lymphoma of the glands. Literature review and options for best pract...
https://doi.org/10.1016/j.critrevonc.2019.01.005
Critical Reviews in Oncology/hematology; Belkacemi Y, Sio TT et. al.

Mar 2nd, 2019 - Primary extranodal non-Hodgkin's lymphomas (EN-NHL) are a heterogeneous group of malignancies that involve numerous entities with significant difference in terms of tumor site locations, prognostic factors, biology expression, and therapeutic opti...

see more →

Drugs  362 results see all →

Clinicaltrials.gov  867 results

Doxorubicin, CC-(486) (5-azacitidine), Romidepsin, and Duvelisib (hARD) for T-cell Lymphoma
https://clinicaltrials.gov/ct2/show/NCT04639843

Aug 12th, 2022 - Background: T-cell lymphomas (TCLs) are a heterogeneous group of lymphoid malignancies defined by clonal proliferation of post-thymic T lymphocytes. Patients with newly diagnosed TCLs are most commonly treated with a CHOP (cyclophosphamide, doxoru...

Treatment by a Bispecific CD3xCD20 Antibody for Relapse/Refractory Lymphomas After CAR T-cells Therapy
https://clinicaltrials.gov/ct2/show/NCT04703686

Aug 12th, 2022 - This study is a multicenter phase II trial including 2 cohorts of patients in Refractory/Relapse disease at least 1 month after CAR T-cells therapy: cohort 1: DLBCL patients cohort 2: PMBL, mantle cell lymphoma, transformed indolent NHL (t-iNHL) o...

A Phase I Study of Indenoisoquinolines LMP400 and LMP776 in Adults With Relapsed Solid Tumors and Lymphomas
https://clinicaltrials.gov/ct2/show/NCT01051635

Aug 12th, 2022 - Background: Indenoisoquinolines are non-camptothecin inhibitors of topoisomerase 1 (top1) with improved characteristics over their predecessors. Indenoisoquinolines have better chemical stability, producing stable DNA-top1 cleavage complexes, and ...

Secondary Prophylaxis in Non-Hodgkin Lymphoma (NHL) and Chemotherapy-induced Thrombocytopenia
https://clinicaltrials.gov/ct2/show/NCT01516619

Aug 12th, 2022 - High-dose chemotherapy followed by autologous stem cell transplant is considered standard of care for patients with relapsed and/or refractory aggressive lymphomas. High-dose chemotherapy, with or without ASCT, may also be used as upfront chemothe...

Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lymphoma
https://clinicaltrials.gov/ct2/show/NCT00001337

Aug 12th, 2022 - Background: The treatment of the intermediate and aggressive non-Hodgkin's lymphomas in adults and children commonly induces complete responses in a sizable fraction of the treated population, and about 2/3 of the complete responders appear to hav...

see more →

News  1,046 results

ALCL Increasing Rapidly in US Women as Breast Implants Rise
https://www.medscape.com/viewarticle/977675

Jul 21st, 2022 - The incidence rate of anaplastic large-cell lymphoma (ALCL) of the breast is increasing rapidly among women in the United States, which is consistent with what has been observed in the Netherlands, Australia, and New Zealand, a large cohort study ...

Erythematous Papules on the Ears
https://www.mdedge.com/dermatology/article/256138/dermatopathology/erythematous-papules-ears
Cameron M.B. Zachary, MD, Amir A. Bajoghli, MD et. al.

Jul 8th, 2022 - The Diagnosis: Borrelial Lymphocytoma (Lymphocytoma Cutis) A punch biopsy revealed an atypical lobular lymphoid infiltrate within the dermis and subcutaneous tissue with a mixed composition of CD3+ T cells and CD20+ B cells (quiz image, bottom). I.

Novel gene therapy offers hope for some lymphomas
https://www.mdedge.com/hematology-oncology/article/255338/b-cell-lymphoma/novel-gene-therapy-offers-hope-some-lymphomas
Heidi Splete

Jun 9th, 2022 - Lisocabtagene maraleucel, a novel chimeric antigen receptor (CAR) T-cell product, evoked a clinical response in patients with relapsed or refractory large B-cell lymphoma in a pilot study presented at the annual meeting of the American Society of.

New German Guideline for H. pylori Infection Coming Soon
https://www.medscape.com/viewarticle/975301

Jun 9th, 2022 - The updated German guideline for Helicobacter pylori therapy is expected to be published in June or July. Unlike the previous version, it will state for the first time that experts recommend an infection be treated as soon as it is detected, regar...

A 64-year-old woman presents with a history of asymptomatic erythematous grouped papules on the right breast
https://www.mdedge.com/dermatology/article/254651/dermatopathology/64-year-old-woman-presents-history-asymptomatic
Donna Bilu Martin, MD

May 17th, 2022 - Primary cutaneous marginal zone lymphoma (PCMZL) is a form of cutaneous lymphoma that typically remains indolent and is limited to the skin. Recurrences may occur.

see more →

Patient Education  15 results see all →